ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Wang, Zhijie; Wu, Lin; Li, Baolan; Cheng, Ying; Li, Xiaoling; Wang, Xicheng; Han, Liang; Wu, Xiaohong; Fan, Yun; Yu, Yan; Lv, Dongqing; Shi, Jianhua; Huang, Jianjin; Zhou, Shaozhang; Han, Baohui; Sun, Guogui; Guo, Qisen; Ji, Youxin; Zhu, Xiaoli; Hu, Sheng; Zhang, Wei; Wang, Qiming; Jia, Yuming; Wang, Ziping; Song, Yong; Wu, Jingxun; Shi, Meiqi; Li, Xingya; Han, Zhigang; Liu, Yunpeng; Yu, Zhuang; Liu, An-Wen; Wang, Xiuwen; Zhou, Caicun; Zhong, Diansheng; Miao, Liyun; Zhang, Zhihong; Zhao, Hui广东药学院; 广州医学院; 安徽医科大学; 北京大学; 吉林大学; 南昌大学; 南京大学; 南通大学; 青岛大学; 山东大学; 上海交通大学; 江南大学; 哈尔滨医科大学; 浙江大学; 郑州大学; 同济大学; 西安交通大学; 厦门大学; 中国医科大学; 中国医学科学院; 重庆大学; 中国科学院研究生院; 中国医学科学院北京协和医院; 1
Journal of Clinical Oncology2023-1-20DOI: 10.1200/JCO.22.00727
36被引7阅读
引用收藏
分享

摘要

PURPOSE The CHOICE-01 study investigated the efficacy and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced non-small-cell lung cancer (NSCLC).PATIENTS AND METHODSPatients (N = 465) with treatment-naive, advanced NSCLC without EGFR/ALK mutations were randomly assigned 2:1 to receive toripalimab 240 mg (n = 309) or placebo (n = 156) once every 3 weeks in combination with chemotherapy for 4-6 cycles, followed by the maintenance of toripalimab or placebo once every 3 weeks plus standard care. Stratification factors included programmed death ligand-1 expression status, histology, and smoking status. The primary end point was progression-free survival (PFS) by investigator per RECIST v1.1. Secondary end points included overall survival and safety. RESULTS At the final PFS analysis, PFS was significantly longer in the toripalimab arm than in the placebo arm (median PFS, 8.4 v 5.6 months, hazard ratio = 0.49; 95% CI, 0.39 to 0.61; two-sided P < .0001). At the interim OS analysis, the toripalimab arm had a significantly longer OS than the placebo arm (median OS not reached v 17.1 months, hazard ratio = 0.69; 95% CI, 0.53 to 0.92; two-sided P = .0099). The incidence of grade >= 3 adverse events was similar between the two arms. Treatment effects were similar regardless of programmed death ligand-1 status. Genomic analysis using whole-exome sequencing from 394 available tumor samples revealed that patients with high tumor mutational burden were associated with significantly better PFS in the toripalimab arm (median PFS 13.1 v 5.5 months, interaction P = .026). Notably, patients with mutations in the focal adhesion-PI3K-Akt signaling pathway achieved significantly better PFS and OS in the toripalimab arm (interaction P values <= .001). CONCLUSION Toripalimab plus chemotherapy significantly improves PFS and OS in patients with treatment-naive advanced NSCLC while having a manageable safety profile. Subgroup analysis showed the OS benefit was mainly driven by the nonsquamous subpopulation.

学科与关键词

关键词
PD-1EFFICACYSAFETYNIVOLUMABRECURRENTANTIBODY
相关
加载中…
  • Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations.
    Wang, Jie; Wang, Zhijie; Wu, Lin; Li, Baolan; Cheng, Ying; Li, Xiaoling; Wang, Xicheng; Han, Liang; Wu, Xiaohong; Fan, Yun; Yu, Yan; Lv, Dongqing; Shi, Jianhua; Huang, Jianjin; Zhou, Shaozhang; Han, Baohui; Sun, Guogui; Guo, Qisen; Ji, Youxin; Zhu, XiaoliAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
  • Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations
    Wang, Jie; Wang, Zhijie; Wu, Lin; Li, Baolan; Cheng, Ying; Li, Xiaoling; Wang, Xicheng; Han, Liang; Wu, Xiaohong; Fan, Yun; Yu, Yan; Lv, Dongqing; Shi, Jianhua; Huang, Jianjin; Zhou, Shaozhang; Han, Baohui; Sun, Guogui; Guo, Qisen; Ji, Youxin; Zhu, XiaoliAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
  • A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China
    Zheng, Zhiwei; Zhu, Gaofeng; Cao, Xueqiong; Cai, Hongfu*; Zhu, Huide*Expert Review of Clinical Pharmacology, 2023, 16(3): 267-273.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Clinical Oncology
发表日期
2023-01-20
卷期
第 41 卷, 第 3 期
页码
651-+
DOI
10.1200/JCO.22.00727
语言
ENGLISH
成果收录
SCIE
资助标注
National key research and development project [2019YFC1315700]; CAMS Innovation Fund for Medical Sciences [2021-1-I2M-012]; National Natural Sciences Foundation of China [81871889, 82072586]; Beijing Natural Science Foundation [7212084]; Aiyou Foundation [KY201701]; National Major Science & Technology Major Projects [2017ZX09302009]; Shanghai Science and Technology Committee Technology Grant [17431900700]; Shanghai Junshi Biosciences

作者

  • W

    Wang, Zhijie (第一作者)

  • W

    Wu, Lin

查看全部 67 位作者收起作者
  • L

    Li, Baolan

  • C

    Cheng, Ying

  • L

    Li, Xiaoling

  • W

    Wang, Xicheng

  • H

    Han, Liang

  • W

    Wu, Xiaohong

  • F

    Fan, Yun

  • Y

    Yu, Yan

  • L

    Lv, Dongqing

  • S

    Shi, Jianhua

  • H

    Huang, Jianjin

  • Z

    Zhou, Shaozhang

  • H

    Han, Baohui

  • S

    Sun, Guogui

  • G

    Guo, Qisen

  • J

    Ji, Youxin

  • Z

    Zhu, Xiaoli

  • H

    Hu, Sheng

  • Z

    Zhang, Wei

  • W

    Wang, Qiming

  • J

    Jia, Yuming

  • W

    Wang, Ziping

  • S

    Song, Yong

  • W

    Wu, Jingxun

  • S

    Shi, Meiqi

  • L

    Li, Xingya

  • H

    Han, Zhigang

  • L

    Liu, Yunpeng

  • Y

    Yu, Zhuang

  • L

    Liu, An-Wen

  • W

    Wang, Xiuwen

  • Z

    Zhou, Caicun

  • Z

    Zhong, Diansheng

  • M

    Miao, Liyun

  • Z

    Zhang, Zhihong

  • Z

    Zhao, Hui

  • Y

    Yang, Jun

  • W

    Wang, Dong

  • W

    Wang, Yingyi

  • L

    Li, Qiang

  • Z

    Zhang, Xiaodong

  • J

    Ji, Mei

  • Y

    Yang, Zhenzhou

  • C

    Cui, Jiuwei

  • G

    Gao, Beili

  • W

    Wang, Buhai

  • L

    Liu, Hu

  • N

    Nie, Lei

  • H

    He, Mei

  • J

    Jin, Shi

  • G

    Gu, Wei

  • S

    Shu, Yongqian

  • Z

    Zhou, Tong

  • F

    Feng, Jian

  • Y

    Yang, Xinmei

  • H

    Huang, Cheng

  • Z

    Zhu, Bo

  • Y

    Yao, Yu

  • T

    Tang, Xiongwen

  • Y

    Yu, Jianjun

  • M

    Maher, Ellen

  • F

    Feng, Hui

  • Y

    Yao, Sheng

  • K

    Keegan, Patricia

  • W

    Wang, Jie

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417